Securities code: 002412 securities abbreviation: Hunan Hansen Pharmaceutical Co.Ltd(002412) Announcement No.: 2022-002 Hunan Hansen Pharmaceutical Co.Ltd(002412)
Announcement on abnormal fluctuation of stock trading
The company and all directors guarantee that the contents of the announcement are true, accurate and complete, and there are no false records, misleading statements or major omissions.
1、 Introduction to abnormal fluctuations in stock trading
Hunan Hansen Pharmaceutical Co.Ltd(002412) (hereinafter referred to as “the company”) (Securities abbreviation: Hunan Hansen Pharmaceutical Co.Ltd(002412) , securities code: 002412) the cumulative deviation of the closing price increase of the stock trading price for two consecutive trading days (January 12, 2022 and January 13, 2022) exceeds 20%. According to the relevant provisions of the stock listing rules of Shenzhen Stock Exchange, It belongs to abnormal fluctuation of stock trading.
2、 Description of the company’s concern and verification
In view of the abnormal fluctuation of the company’s stock trading, the company checked the relevant matters and asked the controlling shareholder and actual controller of the company. The relevant information is described as follows:
1. There is no need to correct or supplement the information disclosed by the company in the early stage;
2. No unpublished material information that may or has had a great impact on the stock trading price of the company has been reported by the public media recently;
3. The disclosed business situation and internal and external business environment of the company have not changed significantly recently;
4. The company, the controlling shareholder and the actual controller have no major events that should be disclosed but not disclosed about the company, or major events in the planning stage;
5. The controlling shareholder and actual controller do not buy or sell the company’s shares during the abnormal fluctuation of stock trading;
6. The company did not find any other matters that should be disclosed in the process of attention and verification.
3、 Whether there is a description of information that should be disclosed but not disclosed
The board of directors of the company confirms that as of the date of this announcement, the company has no undisclosed matters or planning, negotiation, intention and agreement related to the matters that should be disclosed in accordance with the relevant provisions of the stock listing rules of Shenzhen Stock Exchange; The board of directors has not been informed that the company has undisclosed information that has a great impact on the trading price of the company’s shares and their derivatives that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips deemed necessary by listed companies
1. Through self-examination, the company does not violate fair information disclosure;
2. At present, the company’s financial data in 2021 is in the process of statistics. If there are relevant circumstances specified in the stock listing rules of Shenzhen Stock Exchange after preliminary accounting by the company’s financial department, the company will issue performance forecast as required, and the company’s performance information in 2021 has not been provided to any third party other than the accounting firm audited by the company;
3. The company solemnly reminds investors: securities times, China Securities News, Shanghai Securities News, securities daily and cninfo (www.cn. Info. Com. CN.) As the information disclosure media selected by the company, all information of the company shall be subject to the relevant announcements published in the above designated media. The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations. Please invest rationally and pay attention to investment risks.
Hunan Hansen Pharmaceutical Co.Ltd(002412) board of directors
January 14, 2022
